Genentech Lung-Cancer Drug Stirs Excitement On Wall Street

When the nation's oncologists get together for their annual meeting next month, Wall Street will be paying special attention. Last month news accidentally leaked before the market close that Genentech's (NYSE:DNA - News) Avastin helps extend the lives of lung-cancer patients. Genentech's shares rose 25% in the last hour of trading -- even though details about the drug remain fuzzy.

Back to news